Erasca Dividende
Zukünftiges Wachstum Kriterienprüfungen 0/6
Erasca does not have a record of paying a dividend.
Wichtige Informationen
n/a
Dividendenausschüttung
-28.5%
Rückkaufsrendite
Gesamte Aktionärsrendite | -28.5% |
Zukünftige Dividendenrendite | 0% |
Wachstum der Dividende | n/a |
Nächster Dividendenzahlungstermin | n/a |
Ex-Dividendendatum | n/a |
Dividende pro Aktie | n/a |
Ausschüttungsquote | n/a |
Aktuelle Dividendenentwicklung
Keine Aktualisierungen
Recent updates
We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth
Oct 15Erasca: New Focus After Restructuring, But Need More Differentiation
Sep 30Is Erasca (NASDAQ:ERAS) In A Good Position To Deliver On Growth Plans?
Feb 21We Think Erasca (NASDAQ:ERAS) Needs To Drive Business Growth Carefully
Nov 16Companies Like Erasca (NASDAQ:ERAS) Are In A Position To Invest In Growth
Jun 28We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth
Jan 20Erasca forms clinical trial partnership with Pfizer for cancer therapy
Oct 20Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation
Sep 23Erasca adds 10% ahead of R&D Day
Sep 07Erasca, Eli Lilly to collaborate on trial to evaluate combo treatment for two cancers
Jul 18We're Not Very Worried About Erasca's (NASDAQ:ERAS) Cash Burn Rate
Apr 12Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation
Dec 28Stabilität und Wachstum des Zahlungsverkehrs
Rufe Dividendendaten ab
Stabile Dividende: Insufficient data to determine if ERAS's dividends per share have been stable in the past.
Wachsende Dividende: Insufficient data to determine if ERAS's dividend payments have been increasing.
Dividendenrendite im Vergleich zum Markt
Erasca Dividendenrendite im Vergleich zum Markt |
---|
Segment | Dividendenrendite |
---|---|
Unternehmen (ERAS) | n/a |
Untere 25 % des Marktes (US) | 1.5% |
Markt Top 25 % (US) | 4.5% |
Branchendurchschnitt (Biotechs) | 2.2% |
Analystenprognose (ERAS) (bis zu 3 Jahre) | 0% |
Bemerkenswerte Dividende: Unable to evaluate ERAS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Hohe Dividende: Unable to evaluate ERAS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Gewinnausschüttung an die Aktionäre
Abdeckung der Erträge: Insufficient data to calculate ERAS's payout ratio to determine if its dividend payments are covered by earnings.
Barausschüttung an die Aktionäre
Cashflow-Deckung: Unable to calculate sustainability of dividends as ERAS has not reported any payouts.